Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx Group (MDXG) Cost of Revenue: 2011-2025

Historic Cost of Revenue for Mimedx Group (MDXG) over the last 15 years, with Sep 2025 value amounting to $18.7 million.

  • Mimedx Group's Cost of Revenue rose 22.17% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.9 million, marking a year-over-year increase of 24.31%. This contributed to the annual value of $60.1 million for FY2024, which is 9.96% up from last year.
  • According to the latest figures from Q3 2025, Mimedx Group's Cost of Revenue is $18.7 million, which was up 0.20% from $18.7 million recorded in Q2 2025.
  • Mimedx Group's 5-year Cost of Revenue high stood at $18.7 million for Q3 2025, and its period low was $7.1 million during Q4 2021.
  • Its 3-year average for Cost of Revenue is $15.3 million, with a median of $14.9 million in 2024.
  • Per our database at Business Quant, Mimedx Group's Cost of Revenue crashed by 34.38% in 2021 and then spiked by 102.44% in 2022.
  • Over the past 5 years, Mimedx Group's Cost of Revenue (Quarterly) stood at $7.1 million in 2021, then surged by 102.44% to $14.4 million in 2022, then declined by 3.67% to $13.8 million in 2023, then grew by 22.16% to $16.9 million in 2024, then climbed by 22.17% to $18.7 million in 2025.
  • Its Cost of Revenue stands at $18.7 million for Q3 2025, versus $18.7 million for Q2 2025 and $16.6 million for Q1 2025.